Skip to content

Orion Oyj B Price, Chart & Factor Exposure

Free Data & Analytics Access

Next earnings: Wed, Feb 17, 2027, after the market closes · estimates and history

Orion Oyj B · E.ORNBV.HE · Finland
Use symbol E.ORNBV.HE in our API & Excel add-in to retrieve this data ↓
100.40
(0.00%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 50%
Trend 75%
Bubble Risk LOW
Realised Volatility (20D) 21.66%

Orion Oyj B Forecast

Orion Oyj B short-term momentum is positive (up over 3 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (7 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 21.7% a year, a typical one-standard-deviation range is 97.34–103.46 over a week, 94.12–106.68 over a month and 78.65–122.15 over a year. (Signals as of 22 Nov 2026.)

Orion Oyj B Price Chart

MacroFinance.ai
Market/MacroIndicatorNowChangeRange
Quantitative
Orion Oyj B
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Orion Oyj B
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Orion Oyj B
Signal
0
ⓘLatest reading of Signal.
Fundamental
Valuation
Orion Oyj B
P/E
21.37x
Mid-range vs own history
QoQ +12.4%
YoY −20.6%
now 21.370916.71 low28.55 high
ⓘP/E As of 22 Nov 2026.See Orion Oyj B returns when P/E looked like now →Opens Return analysis with the filter P/E within ±5% of today
Orion Oyj B
P/S
6.47x
Stretched vs own history
QoQ +19.2%
YoY +24.8%
now 6.46684.72 low6.66 high
ⓘP/S As of 22 Nov 2026.See Orion Oyj B returns when P/S looked like now →Opens Return analysis with the filter P/S within ±5% of today
Orion Oyj B
P/B
10.07x
Stretched vs own history
QoQ +14.4%
YoY +21.6%
now 10.06656.94 low10.37 high
ⓘP/B As of 22 Nov 2026.See Orion Oyj B returns when P/B looked like now →Opens Return analysis with the filter P/B within ±5% of today
Orion Oyj B
EV/EBITDA
15.78x
Mid-range vs own history
QoQ +13.3%
YoY −21.5%
now 15.779812.24 low21.29 high
ⓘEV/EBITDA As of 22 Nov 2026.See Orion Oyj B returns when EV/EBITDA looked like now →Opens Return analysis with the filter EV/EBITDA within ±5% of today
Orion Oyj B
EV/Sales
6.46x
Stretched vs own history
QoQ +19.0%
YoY +23.4%
now 6.45824.77 low6.66 high
ⓘEV/Sales As of 22 Nov 2026.See Orion Oyj B returns when EV/Sales looked like now →Opens Return analysis with the filter EV/Sales within ±5% of today
Orion Oyj B
FCF Yield
2.8%
Mid-range vs own history
QoQ −18.9%
YoY +6.9%
now 2.82451.73 low3.96 high
ⓘFCF Yield As of 22 Nov 2026.See Orion Oyj B returns when FCF Yield looked like now →Opens Return analysis with the filter FCF Yield within ±5% of today
Orion Oyj B
Earnings Yield
4.7%
Mid-range vs own history
QoQ −11.0%
YoY +26.0%
now 4.67933.5 low5.98 high
ⓘEarnings Yield As of 22 Nov 2026.See Orion Oyj B returns when Earnings Yield looked like now →Opens Return analysis with the filter Earnings Yield within ±5% of today
Orion Oyj B
Market Cap
$14.1B
Highest in 5 years
QoQ +26.1%
YoY +66.9%
now 14076.9888,449 low14,507 high
ⓘMarket Cap As of 22 Nov 2026.See Orion Oyj B returns when Market Cap looked like now →Opens Return analysis with the filter Market Cap within ±5% of today
Balance-Sheet Health
Orion Oyj B
Net Debt
-$19M
Mid-range vs own history
QoQ −852.0%
YoY −121.6%
now -18.8-18.8 low144.5 high
ⓘNet Debt As of 22 Nov 2026.See Orion Oyj B returns when Net Debt looked like now →Opens Return analysis with the filter Net Debt within ±5% of today
Orion Oyj B
Net Debt / EBITDA
-0.02x
Mid-range vs own history
QoQ −776.5%
YoY −110.3%
now -0.0211-0.02 low0.21 high
ⓘNet Debt / EBITDA As of 22 Nov 2026.See Orion Oyj B returns when Net Debt / EBITDA looked like now →Opens Return analysis with the filter Net Debt / EBITDA within ±5% of today
Orion Oyj B
Current Ratio
2.72x
Mid-range vs own history
QoQ +3.2%
YoY +36.6%
now 2.72241.77 low2.72 high
ⓘCurrent Ratio As of 22 Nov 2026.See Orion Oyj B returns when Current Ratio looked like now →Opens Return analysis with the filter Current Ratio within ±5% of today
Orion Oyj B
Quick Ratio
1.61x
Mid-range vs own history
QoQ +8.8%
YoY +35.9%
now 1.61331.13 low1.61 high
ⓘQuick Ratio As of 22 Nov 2026.See Orion Oyj B returns when Quick Ratio looked like now →Opens Return analysis with the filter Quick Ratio within ±5% of today
Orion Oyj B
Debt / Equity
0.09x
Low vs own history
QoQ −14.2%
YoY −70.6%
now 0.08970.09 low0.31 high
ⓘDebt / Equity As of 22 Nov 2026.See Orion Oyj B returns when Debt / Equity looked like now →Opens Return analysis with the filter Debt / Equity within ±5% of today
Orion Oyj B
Piotroski F-Score
7
Mid-range vs own history
QoQ 0.0%
YoY +40.0%
now 75 low7 high
ⓘPiotroski F-Score As of 22 Nov 2026.See Orion Oyj B returns when Piotroski F-Score looked like now →Opens Return analysis with the filter Piotroski F-Score within ±5% of today
Orion Oyj B
Altman Z-Score
17.13
Strong vs own history
QoQ +15.5%
YoY +78.2%
now 17.12618.9 low17.53 high
ⓘAltman Z-Score As of 22 Nov 2026.See Orion Oyj B returns when Altman Z-Score looked like now →Opens Return analysis with the filter Altman Z-Score within ±5% of today
  18 members-only factors: Revenue Growth, Revenue CAGR 3Y, Earnings Growth, EBITDA Growth and moreSign up
Accounting Red Flags
  17 members-only factors: Sloan Accruals, Cash-Earnings Gap, Beneish M-Score, Days Sales in Receivables Index and moreSign up
Global Risk
  22 members-only factors: MacroFinance Risk Index, VIX, VSTOXX, VIX Term Structure and moreSign up
Teal = supportive for Orion Oyj B, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Orion Oyj B fundamentals: income statement, balance sheet & cash flow

Orion Oyj B reported revenue of €1.89bn and net income of €500.3m in FY2025, the year ended 31 December 2025 — revenue up 22.5% and net income up 51.7% on the prior year. Free cash flow was €219.2m. These figures are as reported in the filings, not restated: 26 fiscal years and 89 quarters of history, back to December 2000.

Revenue (FY2025)
€1.89bn
+22.5%
Net income
€500.3m
+51.7%
Gross margin
64.20%
Free cash flow
€219.2m
+6.2%
Net debt
€144.5m
Orion Oyj B income statement, annual, as reported · EUR millions unless stated
EUR millionsFY2025FY2024FY2023FY2022FY2021
Period end31 Dec 202531 Dec 202431 Dec 202331 Dec 202231 Dec 2021
Revenue1,889.51,542.41,189.61,340.71,041.0
Cost of revenue676.5596.0531.9491.7447.5
Gross profit1,213.0946.4657.7849.0593.5
Research & development210.4179.6126.9135.8117.7
Selling, general & admin.—350.2256.0——
Operating income625.0416.6274.9439.6243.3
EBITDA681.7513.5328.2489.6289.4
Interest expense8.78.45.71.81.3
Pre-tax income627.8413.1271.9440.3242.3
Income tax127.583.255.190.848.5
Net income500.3329.9216.8349.5193.8

Download Orion Oyj B fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.ORNBV.HE&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks all 26 fiscal years and 89 quarters, the filing vintages behind each number and API access.
Create free account

Figures in EUR, statements as filed. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic.

Research on Orion Oyj B

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Orion Oyj B Trading Strategies

9 backtested tactical asset allocation strategies hold VGK (European market), the closest tradable exposure to Orion Oyj B; 1 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

Explore all strategies →

Statistical Distribution of Returns

Plus

How Orion Oyj B’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how Orion Oyj B behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About Orion Oyj B (Finland)

Orion Oyj B is a listed security in Finland. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

Frequently asked questions

What is Orion Oyj B?
Orion Oyj B is a listed security in Finland. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest Orion Oyj B price?
The latest close is 100.4 (22 Nov 2026), -0.00% on the day. The price at the top of the page refreshes during the trading day.
Is Orion Oyj B in an uptrend?
As of 22 Nov 2026, short-term momentum is positive (3 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly positive (7 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Orion Oyj B?
20-day realised volatility is 21.7% a year (22 Nov 2026), which implies a typical one-standard-deviation move of about 6.3% over a month and 3.1% over a week.
What factors affect Orion Oyj B?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Orion Oyj B, grouped as Quantitative Factors, Fundamental Factors, Accounting Red Flags, Global Risk Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Orion Oyj B?
9 backtested tactical asset allocation strategies trade Orion Oyj B through VGK; 1 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are Orion Oyj B returns analysed?
The Statistical Distribution of Returns section shows the distribution of Orion Oyj B daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free Orion Oyj B historical data?
In the Free historical data section of this page: the last 10 years of Orion Oyj B daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Orion Oyj B historical data (last 10 years)

Browse or instantly download the last 10 years of Orion Oyj B daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.ORNBV.HE&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-20100.4
2026-11-19100.7
2026-11-18101.4
2026-11-17101.6
2026-11-16103
2026-11-13103
2026-11-12102.7
2026-11-11102.8
2026-11-10101.9
2026-11-09102.2
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychotic; Trexan for rheumatoid arthritis and cancer; Easyhaler product portfolio for asthma and COPD; and Dexdor, Precedex, and Dexmedetomidine products for human use. The company also provides Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, it offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells drugs and products manufactured by other companies. Additionally, the company provides self-care products, including non-prescription medicines, cosmetics, dietary supplements, vitamins, and skincare products. It also offers its products online. The company has a licensing agreement with Tenax Therapeutics, Inc. to develop oral levosimendan (TNX-103) for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF); and Bayer for the development and commercialisation of darolutamide Nubeqa. Orion Oyj was founded in 1917 and is headquartered in Espo, Finland.